Zacks Investment ResearchMon, 29 Jun 2026 15:16:09 GMTUltragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?RARE-2.28%
Seeking AlphaSun, 21 Jun 2026 15:43:38 GMTUltragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease OpportunityRARE-2.28%
Seeking AlphaTue, 09 Jun 2026 23:32:11 GMTUltragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptRARE-2.28%
Zacks Investment ResearchThu, 04 Jun 2026 16:35:57 GMTUltragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?RARE-2.28%
Seeking AlphaWed, 13 May 2026 02:20:46 GMTUltragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 TranscriptRARE-2.28%
CNBCThu, 07 May 2026 10:30:02 GMTRare disease families find roadmap to drug development at bootcampsRARE-2.28%
Zacks Investment ResearchWed, 06 May 2026 17:01:20 GMTRARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal EffectRARE-2.28%
Seeking AlphaWed, 06 May 2026 15:01:36 GMTUltragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call TranscriptRARE-2.28%
Zacks Investment ResearchTue, 05 May 2026 23:00:52 GMTUltragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesRARE-2.28%
Zacks Investment ResearchTue, 05 May 2026 22:11:10 GMTUltragenyx (RARE) Reports Q1 Loss, Misses Revenue EstimatesRARE-2.28%
Zacks Investment ResearchTue, 28 Apr 2026 15:06:52 GMTWill Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should KnowRARE-2.28%
Seeking AlphaSun, 12 Apr 2026 12:47:56 GMTUltragenyx Pharmaceutical: The Market Is Overlooking 2026 CatalystsRARE-2.28%
